• Merus NV MRUS.OQ reported a quarterly adjusted loss of $1.46​​ per share for the quarter ended January 1, lower than the same quarter last year, when the company reported EPS of -43 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 88 cents per share. Wall Street expected results to range from $-1.11 to -72 cents per share.

• Revenue rose 6.7% to $11.77 million from a year ago; analysts expected $7.84 million.

• Merus NV's reported EPS for the quarter was a loss of $1.46​.

• The company reported a quarterly loss of $99.91 million.

• Merus NV shares had risen by 2.6% this quarter and gained 86.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 3.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 16 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Merus NV is $88.00

This summary was machine generated from LSEG data November 1 at 03:47 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)